A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
NCT01076504
Completed
This proposed trial will investigate the combination of amrubicin and carboplatin in the first-line treatment of patients with extensive-stage small cell lung cancer (ES- SCLC). Since myelosuppression is the most common toxicity produced by this drug combination, pegfilgrastim will be administered with each treatment cycle. This trial will be the first clinical trial to evaluate a combination of amrubicin and carboplatin in the first-line treatment of ES SCLC in a U.S. population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2016
Locations: Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana
Conditions: Extensive-Stage Small Cell Lung Cancer
Register for Updates
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
NCT00762034
Completed
This study will compare overall survival in participants with Stage IIIB or IV nonsquamous non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2015
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baton Rouge, Louisiana
Conditions: Non-small Cell Lung Cancer
Register for Updates
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
NCT00043082
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if carboplatin is more effective with or without liposomal doxorubicin in treating recurrent ovarian epithelial or primary peritoneal cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of carboplatin with or without liposomal doxorubicin in treating patients who have recurrent o... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
10/23/2015
Locations: MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana +4 locations
Conditions: Ovarian Cancer, Peritoneal Cavity Cancer
Register for Updates
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
NCT00421889
Completed
The study seeks to assess the safety, pharmacodynamics, pharmacokinetics and efficacy of belinostat (PXD101) administered in combination with carboplatin or paclitaxel or both in patients with solid tumours followed by maximum tolerated dose (MTD) expansion (phase II) in ovarian and bladder cancer patients The clinical trial is now in the MTD (phase II) portion of the study enrolling bladder cancer patients. Enrollment of ovarian patients is complete.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/07/2015
Locations: Hematology and Oncology Specialists, LLC, Covington, Louisiana +1 locations
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer
Register for Updates
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
NCT00873119
Completed
The purpose of this study is to assess efficacy and safety of belinostat in combination with carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2015
Locations: Baton Rouge Medical Center, Baton Rouge, Louisiana
Conditions: Carcinoma of Unknown Primary
Register for Updates
Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
NCT00621049
Completed
Multicenter randomized phase II trial to examine the safety and efficacy of carboplatin, docetaxel, bevacizumab followed by maintenance bevacizumab and erlotinib in patients with completely resected stage IB, II, and select III NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2015
Locations: Hematology Oncology Life Center, Alexandria, Louisiana +1 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
NCT00316186
Completed
This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with extensive disease small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2015
Locations: GSK Investigational Site, Metairie, Louisiana
Conditions: Lung Cancer, Small Cell
Register for Updates
Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer
NCT00254891
Terminated
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel/carboplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2015
Locations: Pfizer Investigational Site, Covington, Louisiana +6 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
NCT00003313
Completed
RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine for non-small cell lung cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of amifostine in treating patients who have stage II or stage III non-small cell lung cancer that cannot be surgically removed and who are undergoing chemotherapy and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2014
Locations: Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana +4 locations
Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
Register for Updates
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
NCT01166542
Completed
The purpose of this Phase 3 study is to evaluate overall survival and progression free survival following intravenous administration of REOLYSIN (Reovirus Serotype 3 Dearing) in combination with paclitaxel and carboplatin versus chemotherapy treatment alone, in patients with metastatic or recurrent Squamous Cell Carcinoma of the Head and Neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2014
Locations: Mary Bird Perkinds Cancer Center - Baton Rouge, Baton Rouge, Louisiana
Conditions: Carcinoma, Squamous Cell of the Head and Neck
Register for Updates
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
NCT00300885
Terminated
A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2014
Locations: Not set, Baton Rouge, Louisiana +1 locations
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates
Combination Chemotherapy in Treating Children With Neuroblastoma
NCT00003093
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Combination chemotherapy plus surgery may be an effective treatment for neuroblastoma. PURPOSE: This phase III trial is studying how well combination chemotherapy followed by surgery works in treating young patients with neuroblastoma.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
07/31/2014
Locations: MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana +3 locations
Conditions: Neuroblastoma
Register for Updates